Author:
Savchenko V. G.,Parovitchnikova E. N.,Skorokhod A. A.,Garmaeva T. Z.,Isaev V. G.,Pivnik A. V.,Vetvitsky V. M.,Attaulakhanov F. I.
Publisher
Springer Berlin Heidelberg
Reference8 articles.
1. Preisler H.D, Gesser T., Azarnia N et al (1984) Relationship between plasma adriamycin levels and outcome of remission induction therapy for acute non-lymphocytic leukemia. Cancer Cemother.Parmacol. 12(2) pp 125–30
2. Gill P.S., Espina B.M., Muggia F et al (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J.Clin.Oncol. v 13 pp 996–1003
3. Verdonck L.R, Lokhorst H.M., Roovers D.J. et al (1998) Multi-drug resistant acute leukemia cells are responsive to prolonged esposure of daunorubicin: implications for liposome-encapsulated daunorubicin Leuk.Res. v 22 N3 pp249–256
4. F. Ataullakhanov, V. Isaev, A. Kohno et al (1997) Pharmacokinetics of doxorubicin in patients with lym-phoproliferative disorders after infusion of doxorubicin-loaded erythrocytes. In: U. Sprandel and J.L. Way (eds) “Erythrocytes as drug carriers in medcine” Plenium Press pp. 137–142
5. Abraham R., Basser R.L., Green M.D. et al (1996) A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy. Drug.Saf. v 15(6) pp 406–29